Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by cardiometabolic risk factors (CMRFs). Treatment of CMRFs is the cornerstone of MASLD management, yet other than weight loss, the association between changes in CMRFs and changes in liver-related measures is not defined. This study aimed to characterize these longitudinal associations using non-invasive measurements of hepatic fibrosis and steatosis.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by cardiometabolic risk factors (CMRFs). Treatment of CMRFs is the cornerstone of MASLD management, yet other than weight loss, the association between changes in CMRFs and changes in liver-related measures is not defined. This study aimed to characterize these longitudinal associations using non-invasive measurements of hepatic fibrosis and steatosis.